Stem cell transplantation for pediatric lymphoma: Past, present and future

Bone Marrow Transplantation

Volumn 41, Issue 2, 2008, Pages 149-158

  Bradley, M B ^a   Cairo, M S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW METASTASIS; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD CARE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOMA; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 38849130633     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705948     Document Type: Review

References (69)

1. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005; 45: 753-769.
2. Bleyer A OLM, Barr RR (eds). Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Publication: Bethesda, MD, 2006 (no. 06-5767).
3. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 1238-1248.
4. Perkins SL, Segal GH, Kjeldsberg CR. Classification of non-Hodgkin's lymphomas in children. Semin Diagn Pathol 1995; 12: 303-313.
5. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification-from controversy to consensus: The R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 2000; 11 (Suppl 1): 3-10.
7. The Non-Hodgkin's Lymphoma Pathologic Classification Project. The National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193-207.
9. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186-193.
10. Patte C. [Non-Hodgkin's lymphomas in children]. Rev Prat 1993; 43: 1665-1668.
11. Meadows AT, Sposto R, Jenkin RD, Kersey JH, Chilcote RR, Siegel SE et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: A report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7: 92-99.
12. Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990; 322: 1169-1174.
13. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin Frankfurt-Münster Group. J Clin Oncol 1995; 13: 359-372.
14. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G et al Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 1992; 80: 2471-2478.
15. Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC et al High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123-132.
16. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
17. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
18. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
19. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 2000; 95: 416-421.
20. Sandlund JT, Pui CH, Santana VM, Mahmoud H, Roberts WM, Morris S et al. Clinical features and treatment outcome for children with CD30 + large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 895-898.
21. Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt Münster group studies. J Clin Oncol 1994; 12: 899-908.
22. Seidemarm K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001; 97: 3699-3706.
23. Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 1999; 36: 313-323.
24. Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998; 16: 897-906.
25. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995; 13: 1080-1088.
26. Pinkerton R. Continuing challenges in childhood non-Hodgkin's lymphoma. Br J Haematol 2005; 130: 480-488.
27. Philip T, Hartmann O, Pinkerton R, Zucker JM, Gentet JC, Lamagnere JP et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: A report from the Societe Francaise d'Oncologie Pediatrique. Blood 1993; 81: 2003-2006.
28. Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993; 11: 1024-1032.
29. Loiseau HA, Hartmann O, Valteau D, McDowell H, Brugieres L, Vassal G et al. High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1991; 8: 465-472.
30. Appelbaum FR, Deisseroth AB, Graw Jr RG, Herzig GP, Levine AS, Magrath IT et al. Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978; 41 1059-1063.
31. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202-207.
32. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean Society of Pediatric Hematology-Oncology. Ann Hematol 2006; 85: 787-794.
33. Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: A report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90: 2921-2930.
34. Chakravarti V, Kamani NR, Bayever E, Lange B, Herzog P, Sanders JE et al. Bone marrow transplantation for childhood Ki-1 lymphoma. J Clin Oncol 1990; 8: 657-660.
35. Bureo E, Ortega JJ, Munoz A, Cubells J, Madero L, Verdaguer A et al Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995; 15 353-359.
36. O'Leary M, Ramsay NK, Nesbit Jr ME, Hurd D, Woods WG, Krivit W et al Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study. Am J Med 1983; 74: 497-501.
37. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Münster group report. Br J Haematol 2006; 133: 176-182.
38. Philip T, Hartmann O, Biron P, Cahn JY, Pein F, Bordigoni P et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118-1124.
39. Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M et al Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and 1-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19: 2390-2396.
40. Levine JE, Harris RE, Loberiza Jr FR, Armitage JO, Vose JM, Van Besien K et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476-2482.
41. Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: Analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437-442.
42. Blay JY, Louis D, Bouffet E, Thiesse P, Biron P, Favrot MC et al. Management of pediatric non-Hodgkin's lymphoma. Blood Rev 1991; 5: 90-97.
43. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993; 11: 2243-2249.
44. Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53-58.
45. Woessman W, Lehhard M, Burkhardt B, Ebell W, Klingebiel T, Mann G et al. Salvage strategy for anaplastic large cell lymphoma in children: prognostic impact of time to relapse and CD3 reactivity. Ann Oncol 2005; 16: V62 (abstract 090).
46. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol 1994; 12: 297-305.
47. Johnston LJ, Horning SJ. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000; 6: 289-300.
48. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E et al Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210-218.
49. Marshall NA, DeVita Jr VT. Hodgkin's disease and transplantation: A room with a (nontransplanter's) view. Semin Oncol 1999; 26: 67-73.
50. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
51. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
52. Schmitz N, Sextro M, Pfistner B, Hasenclever D, Tesch H, Carella A et al. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1). Proc ASCO 1999; 18: 2a (abstract 5).
53. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004; 26: 740-745.
54. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831.
55. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
56. Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernandez JM et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000; 25: 31-34.
57. Harris RE, Termuelin A, Cairo MS, Perkins S, Gross T, Warkentin P et al. Safety and efficacy of CBV followed by autologous PBSC transplant in children with lymphoma after failed induction or first relapse - a Children's Oncology Group Study. Pediatr Blood Cancer 2006; 46 843 (abstract 827).
58. Bradley MB, Cooney E, George D, Garvin J, Del Toro G, Bhatia M et al A pilot study of myeloablative (MA) autologous stem cell transplantation (AutoSCT) followed by reduced intensity (RI) allogeneic stem cell transplantation in children and adolescents with relapsed lymphoma. Biol Blood Marrow Transplant 2006; 12: 115 (abstract 330).
59. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
60. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065-1072.
61. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive nonHodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673-679.
62. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E et al Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 1996; 87: 3625-3632.
63. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955.
64. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446.
65. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.
66. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
67. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
68. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
69. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: A feasibility study. Bone Marrow Transplant 2005; 36: 443-451.